kl003 cell
Transfusion-dependent Beta-Thalassemia
Kanglin Biotechnology (Hangzhou) Co., Ltd.Cell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the Transfusion-dependent Beta-Thalassemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deferasirox Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 4 | BBB |
Deferiprone Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 4 | BBB |
Hydroxyurea Bahria University | Phase 4 | BBB |
TACROLIMUS M.D. Anderson Cancer Center | Phase 4 | BBB |
DESFERRIOXAMINE B Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
kl003 cell is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →